Immunomedics was a biotechnology company focused on the development of antibody-drug conjugates for the treatment of cancer. In 2020, the company was acquired by Gilead Sciences for $21 billion.[1]
History
Immunomedics was founded in July 1982 by David M. Goldenberg.[2]
Michael Pehl was named CEO in December 2017 but left for personal reasons in February 2019.[3] At that time, Dr. Behzad Aghazadeh was named Executive Chairman.[4]
In October 2020, Gilead Sciences acquired the company.